Inactive Instrument

VolitionRX Ltd Share Price OTC Bulletin Board

Equities

VNRX

US9286611077

Biotechnology & Medical Research

Sales 2024 * 2.86M 238M Sales 2025 * 13.48M 1.13B Capitalization 55.15M 4.61B
Net income 2024 * -32M -2.67B Net income 2025 * -22M -1.84B EV / Sales 2024 * 17.8 x
Net cash position 2024 * 4.4M 368M Net cash position 2025 * 25.9M 2.16B EV / Sales 2025 * 2.17 x
P/E ratio 2024 *
-1.82 x
P/E ratio 2025 *
-2.63 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 75.89%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 53 06/11/06
Director of Finance/CFO 54 01/21/01
Chief Operating Officer 51 01/21/01
Members of the board TitleAgeSince
Chief Executive Officer 53 06/11/06
Chairman 80 06/11/06
Director/Board Member 67 06/11/06
More insiders
VolitionRx Limited is a multi-national epigenetics company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
Calendar
More about the company